NCT00541749View on ClinicalTrials.gov

A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

February 28, 2007

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

rhuMAb IFNalpha

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00541749 - A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter